Acrogranin Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor that directly targets Raf kinases and indirectly modulates acrogranin by disrupting the MAPK/ERK signaling pathway. Sorafenib-induced Raf inhibition leads to downstream effects on the MAPK/ERK pathway, influencing acrogranin expression and function in cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that indirectly influences acrogranin by disrupting the MAPK/ERK signaling pathway. U0126-induced MEK inhibition leads to altered phosphorylation cascades, affecting acrogranin expression and function in cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MEK inhibitor that indirectly modulates acrogranin by disrupting the MAPK/ERK signaling pathway. PD98059-induced MEK inhibition leads to altered phosphorylation cascades, affecting acrogranin expression and function in cellular processes. | ||||||
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
BAY 86-9766 is a Raf kinase inhibitor that directly targets the MAPK/ERK signaling pathway, influencing acrogranin expression and function. BAY 86-9766-induced Raf inhibition leads to downstream effects on the MAPK/ERK pathway, modulating acrogranin-related cellular processes. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
PD 184,352 is a selective MEK inhibitor that indirectly modulates acrogranin by disrupting the MAPK/ERK signaling pathway. CI-1040-induced MEK inhibition leads to altered phosphorylation cascades, affecting acrogranin expression and function in cellular processes. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a selective MEK inhibitor that indirectly influences acrogranin by disrupting the MAPK/ERK signaling pathway. Selumetinib-induced MEK inhibition leads to altered phosphorylation cascades, affecting acrogranin expression and function in cellular processes. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH772984 is a selective ERK inhibitor that directly targets the MAPK/ERK signaling pathway, influencing acrogranin expression and function. SCH772984-induced ERK inhibition leads to downstream effects on the MAPK/ERK pathway, modulating acrogranin-related cellular processes. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is a selective ERK inhibitor that directly targets the MAPK/ERK signaling pathway, influencing acrogranin expression and function. FR180204-induced ERK inhibition leads to downstream effects on the MAPK/ERK pathway, modulating acrogranin-related cellular processes. | ||||||